Imbruvica sales declined 18.5% to $866 million due to increased competitive pressure in the United States from novel oral agents and below pre-COVID levels in the CLL market in the United States. Imbruvica sales beat our estimates of $849.7 million. Among the newer medicines, Erleada generated sales of $541 million in the quarter, up 40.9% year over year. Tremfya recorded sales of $752 million in the quarter, up 8.5% year over year driven by share gains in psoriasis and psoriatic arthritis indications, partially offset by a net unfavorable prior period adjustment.